从基础到临床--癌基因ATAD2和肿瘤关系的研究进展  

From basic studies to clinical application: advances in novel oncogene ATAD2 and tumors

作　　者：丁千山[1,2] 王琪[1,3] 孙荣泽[1,2] 沈世强[1,2] 

机构地区：[1]武汉大学人民医院 [2]湖北省人民医院肝胆腔镜外科,湖北武汉430060 [3]湖北省人民医院肿瘤中心,湖北武汉430060

出　　处：《肿瘤》2015年第3期346-350,共5页Tumor

摘　　要：三磷酸腺苷酶家族蛋白2(ATPase family,AAA domain containing 2,ATAD2)是近年来发现的一种癌相关分子,在前列腺癌和乳腺癌等多种恶性肿瘤的发生和发展过程中发挥着重要作用。它是众多转录因子的共激活分子,并能参与表观遗传修饰,促进一系列下游癌基因的表达,进而改变肿瘤细胞的表型。研究还发现,ATAD2表达与肿瘤的组织学分级以及肿瘤转移、疾病复发和患者生存期等相关,提示其可作为肿瘤预后评价分子,具有重要的临床应用价值。另外,ATAD2不仅包括溴结构域(bromodomain,BRD),而且还是与细胞活性相关的ATP酶(ATPases associated with various cellular activities,AAA+ATPase),提示它可能是很有潜力的药物治疗靶点。本文就ATAD2近年来的研究进展和未来可能的研究前景作一综述。ATPase family, AAA domain containing 2 （ATAD2） is a newly uncovered oncogene playing an important role in occurrence and development of prostate cancer, breast cancer and other human malignancies. It is a co- activator of a variety of transcription factors, and it can also modulate genes through epigenetic modifications, resulting in overexpression of its downstream oncogenes, and in turn changing the phenotypes of tumor cells; what＇s more, the expression of ATAD2 is associated with histological grade of cancer, metastasis, disease recurrence and the survival, indicating that it can be used as a molecular marker for prognosis of cancer and has remarkable value in clinical application. Furthermore, ATAD2 contains bromodomain （BRD） and also functions as cellular activity-associated ATPase, which means that ATAD2 may be a potential target for drug therapy. This review summarizes the recent findings and discusses the prospect of this field.

关 键 词：肿瘤 癌基因 腺苷三磷酸酶类 基因表达调控 生物医学研究 三磷酸腺苷酶家族蛋白2 

分 类 号：R730.2[医药卫生—肿瘤]